Diabetes Discourse

Guest: Elena Toschi, MD

Approximately over the last decade, lifespans in the general population have increased, along with a rise in the prevalence of type 1 diabetes in older adult patients. Since each patient has a unique disease, the clinician should personalize and devise the best approach to diabetes management and glycemic targets, as well as manage comorbidities and complications. To learn more, join Dr. Elena Toschi, Director of the Young Adult Program at Joslin Diabetes Center and Assistant Professor of Medicine at Harvard Medical School.

Host: John Buse, MD, PhD
Guest: Kim Boggess, MD

The most common forms of diabetes encountered in pregnant patients include gestational diabetes and preexisting type 2 diabetes. So how does adding metformin to insulin treatment help these patients? Join Dr. John Buse as he talks about the MOMPOD Trial with lead author, Dr. Kim Boggess, Professor of Maternal Fetal Medicine at the University of North Carolina at Chapel Hill.

Guest: R. Paul Wadwa, M.D.

Since young kids have a different activity level and diet than older kids or adult patients, controlling type 1 diabetes in younger patients can be more challenging, and there tends to be more variability in their blood sugars. However, a recent study identified that hybrid closed-loop technology could help give children with type 1 diabetes the best outcomes and quality of life. To learn more, tune in with Dr. Paul Wadwa, Professor of Pediatrics and the Medical Director of the Pediatric Clinic at the Barbara Davis Center for Diabetes at University of Colorado Anschutz Medical Campus.

Host: Carol Wysham, MD
Guest: A. Michael Lincoff, MD

Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who are overweight or obese but do not have diabetes. Not only did semaglutide reduce the risk of cardiovascular death, myocardial infarction, and stroke by 20 percent, but it also significantly reduced the risk of developing diabetes. Dive further into the findings and implications with Dr. Carol Wysham and study author Dr. Michael Lincoff.

Host: John Buse, MD, PhD
Guest: Louis J. Aronne, MD, FTOS

In the SURMOUNT-4 trial, 100 patients with obesity were on tirezpatide for 9 months, and the average weight loss was 20.9 percent. The patients were then randomized to receive either placebo with behavioral intervention or tirzepatide for another year, and the patients in the former group regained a significant amount of weight. Dive further into the study’s findings and implications with Dr. John Buse and Dr. Louis Aronne, the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical College in New York.

Host: John Buse, MD, PhD
Guest: Mary de Groot, PhD

The prevalence of diabetes-related stigma is alarmingly high. In fact, four in five adults have reported experiencing some form of diabetes stigma at some point in their lives. To learn how we as healthcare providers can help reduce this burden for our patients with diabetes, Dr. John Buse speaks with Dr. Mary de Groot, Professor of Medicine and the Associate Vice Chair for Wellness at Indiana University School of Medicine.

Host: Stuart Weinzimer, MD

The artificial pancreas represents the integration of two separate devices: a continuous glucose monitor and an insulin pump. Learn more about this technology and how it can help improve diabetic patients’ quality of life with Dr. Stuart Weinzimer, Interim Section Chief of Pediatric Endocrinology and Diabetes at Yale School of Medicine.

Host: Stuart Weinzimer, MD

From continuous glocuose monitors to insulin pumps, there have been immense technological advancements for patients with type 1 diabetes. Learn more about how these two tools can be used to treat pediatric patients with type 1 diabetes with Dr. Stuart Weinzimer, Interim Section Chief of Pediatric Endocrinology and Diabetes at Yale School of Medicine.

Host: John Buse, MD, PhD
Guest: Michael Fang, PhD

According to a recent study published in the Annals of Internal Medicine, the median age of patients with type 1 diabetes is 24. However, type 1 diabetes that develops in adulthood is often mistakenly identified as type 2 diabetes, resulting in improper treatment. Joining Dr. John Buse to review this study’s key findings and how we can determine if an adult with new-onset diabetes might have type 1 diabetes is Dr. Michael Fang, Assistant Professor in the Division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University.

Host: John Buse, MD, PhD
Guest: Maria Jose Redondo, MD, PhD, MPH

A recent paper focused on a variety of topics associated with type 1 diabetes, including its heterogenenity, endotypes, slowly progressive insulin-dependent diabetes, and the term type 1.5 diabetes. Dive into these topics with Dr. John Buse and Dr. Maria Redondo, Professor of Pediatrics in the Division of Pediatric Diabetes and Endocrinology at Baylor College of Medicine in Texas.

Host: John Buse, MD, PhD
Guest: Helen Murphy, PhD

There are many challenges associated with managing type 1 diabetes (T1D) in pregnant patients, which is why a recent study examined the use of an automated insulin delivery system in this patient population. Using this method, insulin doses were adjusted every 8 to 10 minutes according to a patient’s real-time glucose levels taken from her continuous glucose monitor. As a result, women experienced a higher percentage time in the pregnancy glucose target range, less hyperglycemia, and less gestational weight gain. Learn more about how these findings may impact the management of T1D both during and after pregnancy with Dr. John Buse and Dr. Helen Murphy, a Professor of Medicine in Diabetes and Antenatal Care at the University of East Anglia in the United Kingdom.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: David Selzer, MD

New research suggests that a GLP-1 receptor agonist medication, semaglutide, which has been approved for type 2 diabetes and obesity, could also be used to treat type 1 diabetes in patients. So what are the risks for patients who have type 1 diabetes and who are obese? Joining Dr. Mary Katherine Cheeley to discuss this is Dr. David Selzer, Clinical Instructor of Medicine at NYU Grossman School of Medicine and leads the Medical Weight Loss Program at NYU Langone Medical Associates in the Florida Division.

Host: John Buse, MD, PhD
Guest: Beth Pyatak, PhD, OTR/L

According to a recent study, fluncuations in glucose levels while sleeping can directly impact type 1 diabetes patients’ ability to complete daily activities. In fact, it was found that higher variability overnight led to lower sustained attention and lower engagement in demanding activities the following day. So how can we control glucose levels to help our patients feel better? Explore the study’s key findings and management strategies with Dr. John Buse and Dr. Elizabeth Pyatak, an Associate Professor of Occupational Science and Occupational Therapy at the University of Southern California who worked on the study.

Host: John Buse, MD, PhD
Guest: Simon Heller, MD

Amid the crisis around the cost of diabetes care worldwide, biosimilar insulins could help save millions of dollars and allow more patients to be treated safely and effectively. But how exactly are these products approved, and how do they compare to the original product? Find out with Dr. John Buse and Dr. Simon Heller, Professor of Clinical Diabetes at the University of Sheffield and the Director of Research and Development at Sheffield Teaching Hospitals Foundation Trust in the United Kingdom. Together, they’ll review Dr. Heller’s recent paper on biosimilar basal insulins that was published in Clinical Diabetes.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Elizabeth Cook, PharmD, AE-C, BCACP, CDCES

With a shortage of insulin products in the United States, our diabetic patients are left without lifesaving medications, making this a prominent barrier in clinical practice. However, insulin biosimilars may offer more accessibility and affordability, but what do we know about them? Join Dr. Mary Katherine Cheeley as she speaks with Dr. Lizzie Cook, Clinical Pharmacist at Robert J. Dole Veteran Affairs Medical Center in Wichita, Kansas.

Host: John Buse, MD, PhD
Guest: Jean-Philippe Drouin-Chartier, DtP, PhD

What’s the relationship between ultra-processed food consumption and the risk of developing type 2 diabetes? Find out with Dr. John Buse as he speaks with Dr. Jean-Philippe Drouin-Chartier about his research that sought to answer this exact question. Dr. Drouin-Chartier is an Assistant Professor at the Faculté de Pharmacie at Laval University and a researcher in the Nutrition, Health, and Society Center of the Institute on Nutrition and Functional Foods in Quebec, Canada.

Host: John Buse, MD, PhD
Guest: David Cherney, MD, PhD

There have been several major advances regarding the management of chronic kidney disease in patients with type 2 diabetes over the last 5 years, leading Dr. David Cherney and a team of authors to publish a narrative review on how to best manage these patients using the latest treatment options like SGLT2 inhibitors and non-steroidal MRAs. Tune in to hear him share key highlights from the review with Dr. John Buse. Dr. Cherney is a Professor of Medicine at the University of Toronto and the Director of the Renal Physiology Laboratory at University Health Network in Canada.

Host: John Buse, MD, PhD
Guest: Louis Philipson, MD, PhD

Over the last 15 years, the monogenic diabetes registry now has over 4,000 patients involved, and from that, the RADIANT study was started to identify new kinds of rare and atypical diabetes. So how can genetics testing and the RADIANT study provide atypical diabetes patients with better diagnoses and treatment? Learn more with Dr. John Buse and Dr. Louis Philipson, Professor in the Department of Medicine and Pediatrics at the University of Chicago.

Host: John Buse, MD, PhD
Guest: David Simmons, MD

Gestational hypertension is more common in preeclampsia, and there’s more chance of the baby ending up in the neonatal intensive care unit. So what can we learn from the randomized trials of women patients with gestational diabetes? Learn more with Dr. John Buse as he speaks with Dr. David Simmons, Distinguished Professor of Medicine at the Western Sydney University Macarthur Clinical School in Australia.

Host: John Buse, MD, PhD
Guest: Karen D. Corbin, PhD, RD

One of the biggest missing links in current literature about obesity and the gut microbiome was causality. In an effort to address that gap, a recent clinical trial was conducted, and now, the results are in. So what were the key findings, and how can we translate those findings into clinical practice? Find out how one’s diet can affect the gut microbiome with Dr. John Buse and Dr. Karen Corbin, an Investigator at the AdventHealth Translational Research Institute in Orlando, Florida.

Host: John Buse, MD, PhD
Guest: Anna Kahkoska, MD, PhD

Continuous glucose monitoring (CGM) can help improve glycemic management in patients with type 1 diabetes (T1D), but integrating this technology can be a complex learning process for older adults. So what do we need to consider when it comes to CGM use in older adults? Find out with Dr. John Buse and Dr. Anna Kahkoska, Assistant Professor in the Department of Nutrition and an Adjunct Assistant Professor in the Division of Endocrinology and Metabolism at the University of North Carolina at Chapel Hill. Dr. Kahkoska is also the author of a recent paper, titled “Nothing is linear: Characterizing the determinants and dynamics of CGM use in older adults with type 1 diabetes.”

Host: John Buse, MD, PhD
Guest: Anastassios Pittas, MD, MS

Vitamin D has numerous benefits, and according to a recent study, it can even help reduce the risk of type 2 diabetes in patients with prediabtes. Learn more about the key findings from this research with Dr. John Buse and Dr. Anastassios Pittas, Professor of Medicine and Chief of Endocrinology at Tufts Medical Center.

Host: John Buse, MD, PhD
Guest: Viral Shah, MD

Severe hypoglycemia can lead to dangerous challenges, one of them being an increase in vehicular accidents. Dive into the results from a study that investigated the correlation between the prevalence of hypoglycemia while driving in adults with type 1 diabetes (T1D) and how many of those cases might have led to vehicular accidents with Dr. John Buse and Dr. Viral Shah, Associate Professor of Medicine and Pediatrics at the Barbara Davis Center for Diabetes.

Host: John E. Anderson, MD
Host: John Buse, MD, PhD
Host: Carol Wysham, MD

The guidelines for healthy eating encourage a balance of many things, but doesn’t address the specific amount of carbohydrates, protein, and fat. And with so many fad diets circulating, how do we develop informed dietary recommendations for our patients with type 2 diabetes? Dr. Kathleen Stanley, a registered dietitian and certified diabetes educator with the Baptist Health Center discusses factors to take into consideration when making these decisions.

Host: John Buse, MD, PhD
Guest: Steven Nissen, MD

Among statin-intolerant patients, treatment with bempedoic acid is associated with a lower risk of major adverse cardiovascular events according to a recent study. Dive into the study’s key findings with Dr. John Buse and Dr. Steven Nissen, who published the placebo-controlled study of bempedoic acid among statin-intolerant patients in The New England Journal.

Host: John Buse, MD, PhD
Guest: Elizabeth Selvin, PhD, MPH

As obesity rates continue to rise in adults with type 1 diabetes, what can we do to combat this growing obstacle? Dr. John Buse speaks with an expert in the field, Dr. Elizabeth Selvin, about obesity in patients with type 1 diabetes and shares management strategies.

Host: John Buse, MD, PhD
Guest: Jennifer B. Green, MD

The COORDINATE Study evaluated patients with cardiovascular disease and type 2 diabetes who encounter barriers in receiving newer diabetes medications. To better understand these gaps in care, Dr. John Buse speaks with one of the researchers, Dr. Jennifer Green from Duke University in Durham, North Carolina.

Host: John Buse, MD, PhD
Guest: Ania Jastreboff, MD, PhD

Counseling patients with obesity who are on GLP-1 receptor agonists can be challenging. How can we leverage the biology of GLP-1 receptor antagonists to improve weight loss while avoiding side effects? Dr. John Buse speaks with a leading expert in the field, Dr. Ania Jastreboff, about the role of GLP-1 receptor agonists in weight loss.

Host: John Buse, MD, PhD
Guest: Abbie E. Smith-Ryan, PhD, CSCS*D, FNSCA

There are immeasurable benefits to exercise, but the hard part for patients may be getting started. How can we help our patients make exercise a part of their lives? Dr. John Buse speaks with Dr. Abbie Smith-Ryan, a Professor of Exercise Physiology at the University of North Carolina – Chapel Hill, about the key benefits of exercise and how to encourage them for various patient populations.

Host: John Buse, MD, PhD
Guest: Sue Pedersen, MD, FRCPC

New guidelines published by Obesity Canada take a deep dive into pharmacotherapy and feature the latest recommendations on comorbidities and decision tools. To better understand the impact of these guidelines, Dr. John Buse speaks with one of the guidelines authors, Dr. Sue Pedersen, a specialist in endocrinology and metabolism.

Host: John Buse, MD, PhD
Guest: Silva Arslanian, MD

New research on once-daily semaglutide for adolescent patients with obesity may alter clinicians’ approach to care. What do we need to know? Dr. John Buse speaks with one of the study’s investigators, Dr. Silva Arslanian, from the University of Pittsburgh to dive into this clinical data and explore how these results may change the treatment landscape.

Host: John Buse, MD, PhD
Guest: Jennifer B. Green, MD

What does the latest research on glycemia reduction show us about the impact of glucose-lowering medication in combination with metformin on microvascular and cardiovascular outcomes in patients with type 2 diabetes? Dr. John Buse speaks with one of the study’s investigators, Dr. Jennifer Green, a Professor of Medicine at Duke University, about this emerging data.

Host: John Buse, MD, PhD
Guest: Deborah Wexler, MD

The GRADE study demonstrated the efficacy of different treatment options for patients with type 2 diabetes. To learn more about these treatment options, Dr. John Buse joins one of the study’s investigators, Dr. Deborah Wexler from Harvard Medical School and the Massachusetts General Hospital Diabetes Center, to dive into this study.

Host: John Buse, MD, PhD
Guest: Steven Russell, MD, PhD

Research continues to emerge on the bionic pancreas and its capabilities, and a recent study shows how it can count carbohydrates and lower A1c for patients with type 1 diabetes. To find out how it does, Dr. John Buse is joined by Dr. Steven Russell, an Associate Professor of Medicine at Harvard Medical School at the Massachusetts General Hospital.

Host: John Buse, MD, PhD
Guest: Martin de Bock, PhD FRACP

Recent research has explored the efficacy of open source automated insulin delivery devices for patient with type 1 diabetes. What did these results tell us? Dr. John Buse speaks with Dr. Martin de Bock, a pediatric endocrinologist at the University of Otago in Christchurch, New Zealand, to dive deeper into this research.

Host: John Buse, MD, PhD
Guest: Matthew Crowley, MD

Can telehealth change the way we manage persistently controlled type 2 diabetes (PPDM)? Dr. John Buse speaks with Dr. Matt Crowley, an Associate Professor of Medicine in the Department of Medicine in the Division of Endocrinology, Metabolism and Nutrition at Duke University, to explore some of the research on different methods of telehealth.

Host: John Buse, MD, PhD
Guest: Seth Berkowitz, MD, MPH

Food assistance programs like the Supplemental Nutrition Assistance Program (SNAP) can help relieve food insecurity. But can they also lower healthcare spending? To answer this question, Dr. John Buse sits down with Dr. Seth Berkowitz from the Division of General Medicine and Clinical Epidemiology at the University of North Carolina School of Medicine.

Host: John Buse, MD, PhD
Guest: Ashok Balasubramanyam, MD

Researchers from the GRADE study zeroed in on islet autoimmunity in beta cell dysfunction for patients with type 2 diabetes. What did various treatment options show us? Dr. John Buse speaks with Dr. Ashok Balasubramanyam, a Professor in the Department of Endocrinology, Diabetes and Metabolism at Baylor College of Medicine.

Host: John Buse, MD, PhD
Guest: Jose C. Florez, MD, PhD

Precision medicine may be the future of diabetes treatment. But what’s needed to implement this approach into practice? Here to explore this concept with Dr. John Buse is Dr. Jose Florez, Chief of the Endocrine Division and Diabetes Unit at the Massachusetts General Hospital.

Host: John Buse, MD, PhD
Guest: Carolyn Bramante

Emerging research has shed light on the possibility of generic drugs being repurposed for the treatment of COVID-19. Dr. John Buse discusses metformin, ivermectin, and fluvoxamine with Dr. Carolyn Bramante, an Assistant Professor in the Division of Geriatrics, Palliative and Primary Care at the University of Minnesota Medical School.

Host: John Buse, MD, PhD
Guest: Ania Jastreboff, MD, PhD

In the ongoing battle against obesity, what does the SURMOUNT-1 study tell us about the role of tirzepatide? Dr. Ania Jastreboff, who is an Associate Professor of Medicine and the co-director of Weight Management and Obesity Prevention Program at Yale School of Medicine, chats with Dr. John Buse and this study’s findings.

Host: John Buse, MD, PhD
Guest: Rodica Pop-Busui, MD, PhD

The American Diabetes Association (ADA) published a new consensus report with the American College of Cardiology on heart failure in patients with diabetes. What does this report recommend—and how will these recommendations impact clinical practice? Dr. John Buse speaks with Dr. Rodica Pop-Busui from the University of Michigan about these updated heart failure recommendations.

Host: John Buse, MD, PhD
Guest: Kenneth Cusi, MD, FACP, FACE

The American Association of Clinical Endocrinology (AACE) released new recommendations for the diagnosis and management of NAFLD and NASH. To learn more about these updates, Dr. John Buse speaks with Dr. Kenneth Cusi, who is the Chief of the Division of Endocrinology, Diabetes and Metabolism in the Department of Medicine at the University of Florida.

Host: John Buse, MD, PhD
Guest: David Spence, MD

Pioglitazone was studied in the Insulin Resistance Intervention after Stroke trial, or IRIS for short. What do we need to know about it? Joining Dr. John Buse to share background and clinical data of the impacts observed is Dr. David Spence, a Professor Emeritus of Neurology and Clinical Pharmacology at Western University and the Director of the Stroke Prevention and Atherosclerosis Research Center in London, Ontario.

Host: John Buse, MD, PhD
Guest: Samuel Dagogo-Jack, MD, DSc

Intensive lifestyle interventions have shown to, if not prevent, significantly delay the onset of diabetes. But what do we need to know about these interventions? Joining Dr. John Buse to share clinical data and unravel the impacts of interventions in prediabetic patients is Dr. Samuel Dagogo-Jack from the University of Tennessee Health Sciences Center.

Host: John Buse, MD, PhD
Guest: Domenica M. Rubino, MD

The obesity epidemic affects millions of patients around the world, but a new treatment option may be a game-changer for the treatment landscape. Lead author of the STEP 8 clinical trial, Dr. Domenica Rubino, joins Dr. John Buse to share the insights from this drug trial and how these key clinical findings may impact the obesity treatment landscape.

Host: John Buse, MD, PhD
Guest: Anastasia-Stefania Alexopoulos, MBBS, MHS

Dr. John Buse joins Dr. Anastasia-Stefania Alexopoulos, an endocrinologist, researcher, and Assistant Professor of Medicine in the Department of Medicine at Duke University School of Medicine to share her research on the deintensification of hypoglycemia-inducing medications in diabetic adults.

Host: Carol Wysham, MD
Guest: Jane J. Kim, M.D.

Since 2020, pediatricians have seen a rapid rise in new-onset type 1 diabetes in children. Is this due to the COVID-19 pandemic or an indirect consequence of it? To answer this question, Dr. Jane Kim, a pediatric endocrinologist at Rady Children's Hospital in San Diego, shares what kind of correlation she's seeing.

Host: Carol Wysham, MD
Guest: Jane J. Kim, M.D.

Emerging research details a rapid rise in type 1 diabetes in children amid the COVID-19 pandemic. But what's causing this to happen? To dive into why, Dr. Carol Wysham is joined by Dr. Jane Kim from the Rady Children's Hospital in San Diego.

Host: Carol Wysham, MD
Guest: Rodica Pop-Busui, MD, PhD

Type 2 diabetes can be reflected in a patient's oral health, but can we say the same for patients with type 1 diabetes? Here to dive into that question and to share her latest findings in oral health in patients with type 1 diabetes is Dr. Rodica Pop-Busui, a Larry D. Soderquist Professor of Diabetes and Vice-chair for Clinical Research in the Department of Internal Medicine and also the Director of Clinical Research, Mentoring and Development of M-Diabetes at the University of Michigan.

Host: Carol Wysham, MD
Guest: Alexis McKee, MD

Patient care has evolved amid the COVID-19 pandemic, causing unexpected challenges in managing diseases such as diabetes. Dr. Carol Wysham joins Dr. Alexis McKee, a practicing endocrinologist and an assistant professor of medicine at Washington School of Medicine in St. Louis, Missouri, to discuss how patients have been overcoming challenges in managing diabetes during the pandemic.

Guest: Claresa Levetan, MD

How can we better communicate lifestyle changes and glucose monitoring levels with our diabetic patients? Dr. Claresa Levetan, an endocrinologist at Grand View Health in Lansdale, Pennsylvania, shares key communication strategies she uses with her patients.

Guest: Claresa Levetan, MD

Diabetes impacts around 40 million Americans and 25% of them don't even know they have it. Luckily, Diabetes Alert Day was created to spread awareness of this widespread disease. To help us understand this campaign, Dr. Claresa Levetan, an endocrinologist at Grand View Health in Lansdale, Pennsylvania, shares insights on the importance of Diabetes Alert Day.

Host: John E. Anderson, MD
Guest: Scott Pilla, MD, MHS

One of the most serious side effects of diabetes, hypoglycemia can lead to severe consequences, and keeping up with the latest in care can help us prevent this complication. To share the latest updates, Dr. John Anderson is joined by Lead Researcher Dr. Scott Pilla to share insights from his recent studies on hospital utilization and primary care communication for patients with diabetes.

Host: Carol Wysham, MD
Guest: Deepak Vashishth, PhD
Guest: Bowen Wang

Can we predict when a patient with COVID-19 requires hospitalization? To answer this question, Dr. Carol Wysham is joined by Dr. Deepak Vashishth and Mr. Bowen Wang from the Rensselaer Polytechnic Institute to share data from their study on the impact of glycemic levels and common medications on COVID-19 severity in patients with type 2 diabetes.

Host: John E. Anderson, MD
Guest: Elizabeth A. Beverly, PhD

Current treatment strategies for diabetic patients focus on behavioral and clinical targets alone, but can shared experiences and peer support improve care? To learn more about this, Dr. John Anderson talks to Dr. Elizabeth Beverly from the Ohio University Heritage College of Osteopathic Medicine to discuss her recent study on positive experiences for patients living with type 1 or type 2 diabetes.

Host: Carol Wysham, MD
Guest: Christopher Taylor, PhD, RDN, LD, FAND

Dr. Carol Wysham meets with Dr. Christopher Taylor, Professor of Medical Dietetics at the Ohio State University School of Health and Rehabilitation Sciences, to take a look at low protein intake and its overall impact on diabetic patients.

Host: John E. Anderson, MD
Guest: Simon Heller, MD

What causes sudden death in patients with type 1 diabetes? Dr. Simon Heller, a Professor of Clinical Diabetes at the University of Sheffield, discusses severe hypoglycemia and cardiovascular risk in patients with both type 1 and type 2 diabetes and what clinicians to look for.

Host: John E. Anderson, MD
Guest: Simon Heller, MD

Dr. Simon Heller, a Professor of Clinical Diabetes at the University of Sheffield, discusses glucose-lowering studies and talks about the link between hypoglycemia and thrombosis in patients with diabetes.

Host: John E. Anderson, MD
Guest: Simon Heller, MD

Dr. Simon Heller, a Professor of Clinical Diabetes at the University of Sheffield, and honorary consultant physician with the NHS Foundation Trust in the United Kingdom, reflects on the steps we can take to prevent severe hypoglycemia and reduce cardiovascular risk in diabetic patients.

Host: John E. Anderson, MD
Host: John Buse, MD, PhD
Host: Carol Wysham, MD

John Anderson joins fellow Diabetes Discourse hosts John Buse and Carol Wysham to explore exciting clinical trial results presented at this year's Scientific Session of the American Diabetes Association.

Host: John E. Anderson, MD
Guest: Michael Greenberg, MD

Dr. John Anderson joins Dr. Michael Greenberg, host of DermConsult, to discuss skin diseases that dermatologists should be aware of in patients with diabetes.

Host: Carol Wysham, MD
Guest: Kristen Nadeau, MD, MS

Is there a link between type 2 diabetes and obesity? Dr. Carol Wysham joins Dr. Kristen Nadeau, a Professor of Pediatric Endocrinology at the University of Colorado School of Medicine, to review her research on type 2 diabetes and what it could mean for our patients.

Host: John E. Anderson, MD
Guest: Raghu Mirmira, MD,PhD

When treating type 1 diabetes, should we be focusing on disease prevention rather than reversal? Dr. John Anderson takes a look at prevention tactics for type 1 diabetes progression with Dr. Raghu Mirmira, a Professor of Medicine and the Director of the Translational Research Center at the University of Chicago.

Host: Carol Wysham, MD
Guest: Irl Hirsch, MD, MACP

How is technology like continuous glucose monitors impacting the way we care for patients with diabetes, especially amid the COVID-19 pandemic? To learn more about the technological advancements in diabetes care, Dr. Carol Wysham speaks with Dr. Irl Hirsch, a Professor in Diabetes Treatment and Teaching Chair at the University of Washington School of Medicine in Seattle, Washington.

Host: Carol Wysham, MD
Guest: Irl Hirsch, MD, MACP

Why was there so much discordance between some patients’ GMI and their measured A1C? That’s the exact question Dr. Irl Hirsch from the University of Washington School of Medicine asked and explored in a paper he recently co-authored. And now Dr. Hirsch is here to share his findings.

Host: John Buse, MD, PhD
Guest: Anne Louise Peters, MD

SGLT-2 inhibitors have been authorized for diabetic patients in Europe, but is it close to receiving FDA approval in the U.S.? Dr. Anne Peters of USC speaks with Dr. John Buse about SGLT-2 inhibitors and considerations for diabetic ketoacidosis, heart failure, and chronic kidney disease.

Host: John Buse, MD, PhD

It can be tempting for patients to undermine the seriousness of diabetes. But in recognition of Diabetes Alert Day, Dr. John Buse explains why we need to set the record straight.

Host: John Buse, MD, PhD

How early should we start screening for diabetes, and what tools are available to us? In recognition of Diabetes Alert Day, Dr. John Buse reviews the current screening tests and recommendations for those who are at risk of diabetes.

Host: John E. Anderson, MD
Host: John Buse, MD, PhD
Host: Carol Wysham, MD

The outbreak of the COVID-19 pandemic has pushed healthcare professionals to adjust the way they treat patients with chronic conditions like diabetes. Tune in to hear Drs. John Anderson, John Buse, Carol Wysham share their experience caring for patients with diabetes amid the pandemic.

Guest: Paresh Dandona, MD, PhD
Host: Farhad Zangeneh, MD

Host Dr. Farhad Zangeneh welcomes Paresh Dandona MD, PhD, Professor and Chief of Endocrinology in the Department of Medicine at the University of Buffalo. His Specialty and Research Focus are in Endocrinology, Diabetes and Metabolism. He is also the Founder & Medical Director of the Diabetes-Endocrinology Center of Western New York. In this program, Dr. Dandona will be discussing insulin induced cardioprotection, inflammatory and oxidative stress in acute myocardial infarction. He will also review hyperglycemia and cardiotoxicity in acute myocardial infarction. Please take a listen!

Guest: Robert A. Rizza, MD
Host: Farhad Zangeneh, MD

What are the sources of glucose in the body? Is diabetes a pancreatic disease or a hepatic disease? What is the importance of glucose toxicity in Type 1 or Type 2 diabetes patients? To answer these questions and many more, join our host Dr. Farhad Zangenh in a discussion with Dr. Robert Rizza, an authority in the regulation of carbohydrate metabolism in humans, and the Executive Dean for Research at Mayo Clinic. Download the podcast and listen in!

Host: Farhad Zangeneh, MD
Guest: Paul Jellinger

In diabetes management, clinicians typically measure glycemic control with fasting plasma glucose (FPG) and premeal glucose measurements, and HbA_1c. And, the goals for each of these measurements have been established based on the results of many clinical trials. However, the majority of patients with diabetes fail to achieve these glycemic goals. Elevated postprandial glucose (PPG) concentrations may contribute to suboptimal glycemic control. Host Dr Farhad Zangeneh is joined by Dr. Paul Jellinger who will address the issue of postprandial glucose and its complications.

Paul S. Jellinger, MD and Master of the American College of Endocrinology (MACE) serves as Professor of Medicine on the voluntary faculty at the University of Miami and served as Chief of the Section of Endocrinology at Memorial Regional Hospital in Hollywood, Florida. Dr. Jellinger served as president of the AACE, the ACE and the Florida Endocrine Society. Dr. Jellinger has been active on the AACE Board of Directors.

Guest: Yehuda Handelsman, MD
Host: Farhad Zangeneh, MD

Dr Farhad Zangeneh is joined by Dr. Yehuda Handelsman, Medical Director at the Metabolic Institute of America; President of the American Association of Clinical Endocrinologists; and, Chair & Program Director, "Annual World Congress on Insulin Resistance, Diabetes & CVD".Dr. Handelsman will discuss the recent growing concerns between diabetes, anti-diabetes agents, and the increased prevalence of various cancers. Currently available data are limited, controversial, and confusing. The AACE and health care providers believe that this is a critically important area that needs further clarification.

Host: Farhad Zangeneh, MD
Guest: James R. Gavin, III, MD, PhD

Host Dr Farhad Zangeneh welcomes James R. Gavin III, MD, PhD, clinical professor of medicine at Emory University School of Medicine and at the Indiana University School of Medicine. Together they will explore the trends in the growth of diabetes in African Americans, the policies needed to address these problems, and some of the barriers that prevent better outcomes in diabetes care for African Americans and other high-risk minorities.

James R. Gavin III, MD AND PHD, clinical professor of medicine at Emory University School of Medicine and at the Indiana University School of Medicine. Dr. Gavin serves as CEO and Chief Medical Officer of Healing Our Village, Inc. He also belongs to a number of organizations, including the Institute of Medicine, the American Diabetes Association (ADA), the American Society of Clinical Investigation, the American Association of Physicians, and the Atlanta Rotary Club.

Guest: Kathleen "Kittie" Wyne, MD, PhD, FACE
Host: Farhad Zangeneh, MD

Host Dr. Farhad Zangeneh welcomes Dr. Kathleen "Kittie" Wyne from the The Methodist Hospital Research Institute (TMHRI) in Houston where she also coordinates their clinical research program in The Diabetes Research Center. Dr. Wyne discusses the changing classification of diabetes and pre-diabetes and how and when we should make the diagnosis. She also discusses the criteria for both diabetes and pre-diabetes and the tools available for clinicians.

Guest: George Grunberger, MD, FACP, FACE
Host: Farhad Zangeneh, MD

Host Dr. Farhad Zangeneh welcomes Dr. George Grunberger on a discussion on how to attain the best glucose control for our patients and how to do it safely. The discussion stems from altering lifestyle changes for our patients, addressing how to set individualized targets for our patients and identifying whats the best course of action.

Dr. George Grunberger, founder and chairman of the Grunberger Diabetes Institute in Bloomfield Hills, Michigan. He is Clinical Professor of Internal Medicine and Molecular Medicine & Genetics at Wayne State University School of Medicine in Detroit. Dr. Grunberger has published well over 100 original peer-reviewed manuscripts in addition to reviews and book chapters. His research spans subjects from molecular underpinning of insulin resistance to clinical studies on diabetes and its complications.

Guest: Aaron Kowalski, PhD
Host: Timothy Bailey, MD

The artificial pancreas project lead by the Juvenile Diabetes Research Foundation has made tremendous progress towards eventual outpatient clinical studies. A recent panel of experts met with the FDA and NIH to determine appropriate guidelines. What are regulatory guidelines for the artificial pancreas project? Join guest host Dr. Timothy Bailey and his guest, Assistant Vice President and Director of Glucose Control Research at the Juvenile Diabetes Research Foundation, Dr. Aaron Kowalski as they discuss developments from controlled inpatient settings to real-world conditions and the need for regulation.

Guest: Thomas Moore, MD
Host: Steven Edelman, MD

New screening standards for gestational diabetes could significantly increase the number of women and babies we identify as at-risk. Guest host Dr. Timothy Bailey talks with Dr. Thomas Moore, chairman of the department of reproductive medicine at the University of California, San Diego, about diabetes in pregnancy, and how gestational diabetes affects infant, childhood, and even adolescent obesity and overall health. They discusses screening methods for gestational diabetes, who is at risk, and the benefit from dietary interventions.

Host: Steven Edelman, MD
Guest: Sunder Mudaliar, MD

How can we prevent and treat pre-diabetes? Can a pill delay or prevent the onset of disease in high-risk individuals? Host Dr. Steven Edelman talks to Dr. Sunder Mudaliar, clinical professor of medicine in the division of endocrinology and metabolsim at the VA Medical Center and University of California San Diego School of Medicine, about the data on pioglitazone for diabetes prevention and the results of the ACT NOW study.

Host: Steven Edelman, MD
Guest: Lutz Heinemann, PhD

Biosimilar insulin is an attractive market to a number of American and European pharmaceutical companies. Biosimilar insulin manufacture is complicated for a number of reasons. Guest host Dr. Timothy Bailey talks with Dr. Lutz Heinemann, director of scientific services at Profil Institute for Clinical Research in San Diego and headquartered in Neuss, Germany, about the challenges and guidelines around producing safe and effective biosimilars. And, for healthcare providers, what are the practical aspects of switching to a biosimilar insulin?

Guest: Janis Roszler, CDE, RD, LD/N
Host: Steven Edelman, MD

About half of men with diabetes experience some kind of sexual dysfunction, and the numbers for women are not far behind. This week's guest, Janis Roszler, ceritified diabetes educator and marriage and family therapist, discusses the connection between sexual function and both physical and emotional well-being in patients living with diabetes. She makes the case for adding sexual function to the list of issues we talk about with patients who have diabetes. What are the causes of sexual dysfunction in these patients? Could drugs that help men also help women? Dr. Steven Edleman hosts.

Guest: Stephen Ponder, MD, CDE
Host: Steven Edelman, MD

A new study suggests newly trained physicians may not be adequately prepared to treat patients with diabetes. Host Dr. Steven Edelman, talks with Dr. Stephen Ponder, pediatric endocrinologist at Texas A&M, with 27 years of professional experience in the management of children with diabetes, about the implications for the next generation of patients and Dr. Ponder's recommendations for a mentoring system to provide additional training to young physicians.

Guest: John Walsh, PA, CDE
Host: Steven Edelman, MD

Insulin pump practice studies reveal new approaches in the management of diabetes, including carb-counting, carb boluses, hypoglycemia and transdermal insulin drug delivery. What are actual pump practices that lead to improved control? Join host Dr. Steven Edelman and his guest, John Walsh, PA, and certified diabetes educator at Advanced Metabolic Care and Research in Escondido, California, as they discuss pump practices that lead to improved control.

Guest: Jane Seley, DNP, MPH
Host: Steven Edelman, MD

The transition from hospital to home for patients with diabetes can be challenging, from glycemic targets, guidelines for initiating insulin therapy, the various types of insulin and oral agents to general nutrition. What are the current recommendations for the transition from hospital to home for patients living with diabetes? Join host Dr. Steven Edelman and his guest, Dr. Jane Jeffrie Seley, diabetes nurse practitioner and certified diabetes educator at New York-Presbyterian Hospital Weill Cornell Medical Center, as they discuss the differences in the current AACE and ADA inpatient and outpatient recommendations.

Guest: Linda Siminerio, RN, PhD, CDE
Host: Steven Edelman, MD

Insulin therapy can be challenging for both the patient with diabetes and their healthcare provider— from needle phobia to weight gain. How can healthcare providers shorten the learning curve to understanding insulin and its benefits? Join host Dr. Steven Edelman and his guest, Dr. Linda Siminerio, associate professor at the University of Pittsburgh School of Medicine, as they discuss insulin fact and fallacy for patients and providers.

Guest: David Henderson, MD
Host: Steven Edelman, MD

Antipsychotic medications have dramatically increased in prescriptions, including additional FDA-approved usages for bipolar and depression as well as off-label use. Side effects of these drugs, such as abdominal weight gain, lipid and blood pressure changes, and elevations in fasting glucose, may contribute to metabolic syndrome. What are the impacts of increased use of antipsychotic medications on diabetes? Join host Dr. Steven Edelman and his guest, associate professor of psychiatry at Harvard Medical School, Dr. David Henderson, as they discuss the need for healthcare providers to be proactive: understanding the patient's risk factors, medical history and the risk-benefit ratio in order to treat effectively.

Guest: Jeffrey La Belle, PhD
Host: Steven Edelman, MD

Many patients do not test blood glucose levels as often as they should, due to pain associated with the finger stick, as well as the need for an excess of testing paraphernalia. This week's guest discusses a potential non-invasive test on the horizon that would use tears to measure glucose levels. Dr. Jeffrey La Belle, biomedical engineering research professor in the School of Biological and Health Systems Engineering in Arizona State University's Ira A. Fulton Schools of Engineering and the Biodesign Institute, discusses promising new research in testing that may improve effectiveness and compliance with measuring blood glucose.

Guest: Eric Rackow, MD
Host: Steven Edelman, MD

The percentage of healthcare spending on chronic illnesses is increasing exponentially; critically for patients with diabetes. How can healthcare providers help their aging population to manage their diabetes and avoid costly hospital stays through home care management? Join host Dr. Steven Edelman and his guest, professor of medicine at the New York University School of Medicine, Dr. Eric Rackow, as they discuss new approaches for home care management strategies for patients living diabetes.

Guest: Natalie Strand, MD
Host: Steven Edelman, MD

The management of diabetes is an ongoing challenge for both the healthcare provider and patient in terms of balancing insulin regimens, glucose monitoring, diet and exercise. How does the diabetes educator help to "win the race" for a patient with diabetes? Join host Dr. Steven Edelman and his guest, interventional pain management physician and winner of the Amazing Race, Dr. Natalie Strand, as they discuss the integral role of the diabetes educator in the management of diabetes.

Guest: Simon Heller, MD
Host: Steven Edelman, MD

In 2004 the American Diabetes Association working group defined the threshold of hypoglycemia as 70 mg/dl. The clinical definition continues to attract controversy with a standard vs. dynamic solution. What are considerations that need to be made in terms of the clinical definition of hypoglycemia? Join host Dr. Steven Edelman and his guest, professor of clinical diabetes at the University of Sheffield, Dr. Simon Heller, as they discuss the challenge with the current threshold of hypoglycemia.

Guest: Patrick O'Connor, MD
Host: Steven Edelman, MD

A push away from the "one size fits all" approach to diabetes care, including subgroup analyses, patient preference, genetic factors and electronic records, is changing the way healthcare providers are caring for their patients. How do healthcare providers reflect these changes in their practices? Join host Dr. Steven Edelman and his guest, clinician of family medicine and senior investigator for HealthPartners, Dr. Patrick O'Connor, as they discuss a personalized approach to diabetes management.

Guest: Eric Topol, MD
Host: Timothy Bailey, MD

The challenges of treating diabetes include long-term monitoring and management, lifestyle change and adherence to medication. How are digital technology and genomics shaping the management of diabetes? Join guest host Dr. Timothy Bailey and his guest Dr. Eric Topol, director of the Scripps Translational Science Institute, as they discuss how digital technologies can improve glucose monitoring and genomics is leading to individualized treatment. Dr. Topol, who does not have diabetes, describes his personal experience living with continuous glucose monitoring for one week.

Disclosures

Dr. Eric Topol has disclosed that he has received grants for clinical research from sanofi-avenitis. Dr. Topol has also disclosed that he has served as an advisor or consultant to sanofi-aventis and Daiichi Sankyo.

Guest: Elizabeth Kovacs, PhD
Host: Timothy Bailey, MD

Experimental approaches, including the suppression of certain immune cells to speed difficult wounds, may lead healthcare professionals to advances in the treatment of diabetic wounds. What are the therapeutic strategies and implications for our patients with diabetes? Join guest host Dr. Timothy Bailey and his guest, director of research at the Burn & Shock Trauma Institute at Loyola University Medical Center, Dr. Elizabeth Kovacs, as they discuss the latest research in suppressing certain immune cells to speed healing of slow-to-heal wounds.

Guest: Louis Aronne, MD
Host: Steven Edelman, MD

Treatment regimens for diabetes and obesity are merging. Healthcare professionals are taking a new view to the management of diabetes including rearranging diabetes medication regimens from a glucose control and weight-neutral perspective. What do healthcare professionals need to know to help their patients manage their diabetes? Join host Dr. Steven Edelman and his guest, clinical professor of medicine at Cornell Medical College, Dr. Louis Aronne, as they discuss considerations of drug therapies as weight neutral for treating their patients with type 2 diabetes.

Guest: Juan Pablo Frías, MD
Host: Steven Edelman, MD

Patients living with type 1 diabetes who are involved in athletics present particular challenges to approaching to their management, medication regimen and nutrition. How can healthcare professionals help their type 1 athletes optimize their performance and manage their diabetes? Join host Dr. Steven Edelman and his guest, director of research at TeamType1, Dr. Juan Frias, as they discuss restrictions, research, monitoring and adjusting insulin therapy for endurance type 1 athletes.

Guest: William Polonsky, PhD, CDE
Host: Timothy Bailey, MD

A majority of type 2 patients do not understand the benefits of structured self-monitoring of blood glucose and healthcare professionals lack the time to explain the values and the time to review the values themselves. What is the benefit of structured self-monitoring of blood glucose in patients with type 2 diabetes? Join guest host Dr. Timothy Bailey and his guest, founder of the Behavioral Diabetes Institute, Dr. William Polonsky, as they discuss the challenges and barriers for both healthcare professionals and patients with structured self-monitoring of blood glucose.

Guest: Candis Morello, PharmD, CDE
Host: Steven Edelman, MD

Medication adherence is one of the most challenging aspects of managing patients with diabetes. The majority of diabetes patients taking more than one oral agent do not adhere to their prescribed regimens. What is the key to successful adherence to drug regimens in patients living with diabetes? Join host Dr. Steven Edelman and his guest, associate professor of clinical pharmacy at UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, Dr. Candis Morello, as they discuss results from a recent study on medication adherence for patients living with diabetes.

Host: Steven Edelman, MD
Guest: Azza El-Remessy, PhD, RPh

Retinopathy is one of the most common complications for patients living with diabetes but there are few treatment options and no early-stage interventions. How is research helping to pinpoint potential targets for early intervention and a possible oral treatment? Join host Dr. Steven Edelman and his guest, assistant professor and director of clinical and experimental therapeutics at the University of Georgia, Dr. Azza El-Remessy, as they discuss the latest research into the potential of statins to prevent diabetic-related blindness.